MURRAY HILL, N.J.--(BUSINESS WIRE)--Nov. 8, 2007--C. R. Bard, Inc. (NYSE: BCR) today announced that it has received clearance from the United States Food and Drug Administration to market its Agento(TM) IC silver-coated endotracheal tube. The clearance includes claims for the reduction of microbiologically confirmed ventilator associated pneumonia (VAP). Management is currently evaluating the benefits of launching the Agento(TM) IC product in conjunction with the potential publication of the clinical trial results in a major peer-review medical journal. The product will be marketed by Bard's Medical division located in Covington, Georgia.

VAP is one of the most costly hospital acquired infections and is associated with high patient mortality and morbidity. It is especially prevalent in hospital intensive care units in cases where a ventilated patient has an endotracheal tube in place for more than 24 hours. The Agento(TM) IC product incorporates Bard's proprietary silver colloid polymer technology which allows the tube to elute microbicidal levels of silver ions.

C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our September 30, 2007 Form 10-Q/A for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

CONTACT: C. R. Bard, Inc.
Investor Relations:
Eric J. Shick
Vice President, Investor Relations
908-277-8413
or
Media Relations:
Holly P. Glass
Vice President, Government and Public Relations
703-754-2848

SOURCE: C. R. Bard, Inc.